Galectin Therapeutics Inc (NASDAQ: GALT) has experienced a rise in its stock price by 7.27 compared to its previous closing price of 1.65. However, the company has seen a gain of 12.03% in its stock price over the last five trading days. globenewswire.com reported 2025-01-10 that NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented during the 2025 MASH-TAG Conference, being held January 9-11, 2025 in Park City, Utah. Additionally, Company’s executive leadership will be hosting one-on-one meetings in San Franscico January 13-16, 2025, during JP Morgan Healthcare Conference and is looking forward to engaging external stakeholders on NAVIGATE topline results and discussing next steps for the belapectin program.
Is It Worth Investing in Galectin Therapeutics Inc (NASDAQ: GALT) Right Now?
Company’s 36-month beta value is 0.67.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for GALT is 43.02M, and currently, short sellers hold a 18.87% ratio of that floaft. The average trading volume of GALT on March 26, 2025 was 436.06K shares.
GALT’s Market Performance
GALT’s stock has seen a 12.03% increase for the week, with a 21.23% rise in the past month and a -11.50% fall in the past quarter. The volatility ratio for the week is 9.15%, and the volatility levels for the past 30 days are at 8.16% for Galectin Therapeutics Inc The simple moving average for the past 20 days is 10.35% for GALT’s stock, with a -17.25% simple moving average for the past 200 days.
Analysts’ Opinion of GALT
Many brokerage firms have already submitted their reports for GALT stocks, with H.C. Wainwright repeating the rating for GALT by listing it as a “Buy.” The predicted price for GALT in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on August 13, 2020 of the previous year 2020.
B. Riley FBR, on the other hand, stated in their research note that they expect to see GALT reach a price target of $11. The rating they have provided for GALT stocks is “Buy” according to the report published on February 13th, 2019.
H.C. Wainwright gave a rating of “Buy” to GALT, setting the target price at $10 in the report published on December 07th of the previous year.
GALT Trading at 24.37% from the 50-Day Moving Average
After a stumble in the market that brought GALT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -58.53% of loss for the given period.
Volatility was left at 8.16%, however, over the last 30 days, the volatility rate increased by 9.15%, as shares surge +20.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +60.91% upper at present.
During the last 5 trading sessions, GALT rose by +12.03%, which changed the moving average for the period of 200-days by -35.40% in comparison to the 20-day moving average, which settled at $1.6040. In addition, Galectin Therapeutics Inc saw 37.21% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GALT starting from Shlevin Harold H., who purchase 6,500 shares at the price of $1.16 back on Dec 30 ’24. After this action, Shlevin Harold H. now owns 15,206 shares of Galectin Therapeutics Inc, valued at $7,540 using the latest closing price.
Jamil Khurram, the Chief Medical Officer of Galectin Therapeutics Inc, sale 13,654 shares at $0.88 during a trade that took place back on Dec 23 ’24, which means that Jamil Khurram is holding 26,346 shares at $12,044 based on the most recent closing price.
Stock Fundamentals for GALT
Current profitability levels for the company are sitting at:
- -494.57 for the present operating margin
- 0.66 for the gross margin
The net margin for Galectin Therapeutics Inc stands at -563.46. The total capital return value is set at -10.65.
Based on Galectin Therapeutics Inc (GALT), the company’s capital structure generated 8.64 points at debt to capital in total, while cash flow to debt ratio is standing at -0.32. The debt to equity ratio resting at -1.13. The interest coverage ratio of the stock is -8.49.
Currently, EBITDA for the company is -0.2 million with net debt to EBITDA at -1.92. When we switch over and look at the enterprise to sales, we see a ratio of 2347.64. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.13.
Conclusion
In a nutshell, Galectin Therapeutics Inc (GALT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
